Change search criteria ↓

Search results

15 projects found matching your search criteria:

  1. 1. Novel aspects of the mechanisms of vascular toxicity of tyrosine kinase inhibitors: studies on their proinflammatory act…

    Principal investigator: dr Tomasz Krzysztof Prajsnar

    Uniwersytet Jagielloński, Wydział Biologii

    Call: OPUS 26, Panel: NZ5

  2. 2. Investigating the mechanisms of CD20 downregulation triggered by tyrosine kinase inhibitors in Philadelphia chromosome-p…

    Principal investigator: Krzysztof Domka

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

    Call: PRELUDIUM 22, Panel: NZ5

  3. 3. Effects of tyrosine kinase inhibitors on Syk pathway in eNOS-based platelet subpopulations and on endothelial barrier in…

    Principal investigator: dr hab. Aneta Iwona Radziwon-Balicka

    Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

    Call: POLONEZ BIS 3, Panel: NZ7

  4. 4. Iron chelators as tyrosine kinase inhibitors - a new strategy for the treatment of glioblastoma multiforme

    Principal investigator: dr hab. Anna Dominika Mrozek-Wilczkiewicz

    UNIWERSYTET ŚLĄSKI, Wydział Nauk Ścisłych i Technicznych

    Call: PRELUDIUM BIS 2, Panel: NZ5

  5. 5. Comparative evaluation of effects of tyrosine kinase inhibitors (TKIs) on endothelial function in vivo in mice

    Principal investigator: Brygida Elżbieta Marczyk

    Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

    Call: PRELUDIUM 17, Panel: NZ5

  6. 6. Insights into biological activity and mechanism of action of novel styrylquinazoline derivatives as tyrosine kinase inhi…

    Principal investigator: Katarzyna Anna Malarz

    UNIWERSYTET ŚLĄSKI, Wydział Matematyki, Fizyki i Chemii

    Call: PRELUDIUM 12, Panel: NZ7

  7. 7. Analysis of the effectiveness of anticancer activity of tyrosine kinase inhibitors combined with nanoparticles in in vit…

    Principal investigator: dr Natalia Piergies

    Instytut Fizyki Jądrowej im. Henryka Niewodniczańskiego PAN

    Call: SONATA 11, Panel: ST4

  8. 8. Mechanism regulating vitamin D analog cooperation with cytostatics and tyrosine kinase inhibitors in non-small cell lung…

    Principal investigator: dr Ewa Agnieszka Maj

    Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

    Call: PRELUDIUM 5, Panel: NZ4

  9. 9. New MOF compounds as degradable nanocontainers of tyrosine kinases inhibitors in novel anti-cancer therapy

    Principal investigator: prof. Artur Piotr Terzyk

    Uniwersytet Mikołaja Kopernika, Wydział Chemii

    Call: OPUS 9, Panel: ST5

  10. 10. Analysis of pharmacokinetic, pharmacodynamic and molecular determinants of intolerance and resistance to the Janus kinas…

    Principal investigator: prof. Marta Katarzyna Karaźniewicz-Łada

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

    Call: OPUS 27, Panel: NZ7

  11. 11. Inhibition of p21-Activated Kinase (PAK) as a new molecular target in the treatment of chronic myeloid leukemia (CML)

    Principal investigator: dr hab. Sylwia Flis

    Narodowy Instytut Leków

    Call: OPUS 6, Panel: NZ7

  12. 12. New strategies in the treatment of non-small cell lung cancer based on silk nanocarriers targeting tumor vascularization

    Principal investigator: dr Anna Katarzyna Florczak-Substyk

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

    Call: SONATA 17, Panel: NZ7

  13. 13. RE-SENSE: Dual-loaded lipid nanoparticles to overcome the resistance of non-small cell lung cancer cells to personalized…

    Principal investigator: Mikołaj Czajkowski

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

    Call: PRELUDIUM 20, Panel: NZ7

  14. 14. A novel approach based on the optimized multidrug combination for glioblastoma treatment.

    Principal investigator: prof. Małgorzata Kucińska

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

    Call: SONATA 16, Panel: NZ7

  15. 15. Protein and gene expression analysis in the course of renal cancer stem-like cells' primary resistance to sorafenib in h…

    Principal investigator: Zofia Felicja Bielecka

    Wojskowy Instytut Medyczny

    Call: PRELUDIUM 9, Panel: NZ5

Graphic design and implementation: Jakub Piotrowski